报名：医疗器械政策解读会

Group 1 - The core viewpoint of the article is the recent release of policies by six departments in Beijing aimed at promoting the high-quality development of the medical device industry, establishing a comprehensive policy system covering "R&D—clinical—promotion—industrialization—going abroad" [2] - The policies include support for innovation in R&D, clinical implementation, industrial space, supply chain challenges, AI large models, and international pathways [2] - There are noticeable differences in the direction, mechanisms, and intensity of policies among Beijing, Shanghai, and Shenzhen, with each city having its unique focus and strategies [3] Group 2 - The event scheduled for December 4, 2025, aims to provide an in-depth analysis of Beijing's new medical device policies, focusing on clinical implementation and promotion [4] - Key highlights of the event include the meaning of the "directory + direct hospital recommendation" system, the logic behind the establishment of application demonstration centers and training centers, and the applicable scope of clinical promotion effectiveness rewards (up to 10 million) [4] - The comparison of policy highlights among the three cities will cover Shanghai's focus on high-end devices, payment system reforms, and industrial cluster development [4] Group 3 - Observations on the biopharmaceutical alliance will discuss policy trends over the next 3-5 years and provide strategic recommendations for companies [5] - Shenzhen's policies emphasize clinical trial efficiency, real-world data, and internationalization strategies, highlighting the matching relationship between policies and enterprise development stages [8] - The article raises questions about whether clinical implementation mechanisms will become a competitive focus among cities and the actual impact of AI and large models on medical device companies [8]